Drug-Induced Liver Injury

被引:359
作者
Leise, Michael D. [1 ]
Poterucha, John J. [1 ]
Talwalkar, Jayant A. [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
关键词
HEPATITIS-E VIRUS; ORAL MEDICATIONS; ACETAMINOPHEN HEPATOTOXICITY; FAILURE; SUSCEPTIBILITY; RISK; EPIDEMIOLOGY; DYSFUNCTION; POPULATION; RESISTANCE;
D O I
10.1016/j.mayocp.2013.09.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Drug hepatoxicity can be nonidiosyncratic (predictable), as in the case of acetaminophen, or idiosyncratic (unpredictable). This review article focuses primarily on idiosyncratic drug-induced liver injury (DILI). New epidemiologic data suggest that approximately 20 new cases of DILI per 100,000 persons occur each year. Idiosyncratic DILI accounts for 11% of the cases of acute liver failure in the United States. Risk factors for DILI include medication dose, drug lipophilicity, and extent of hepatic metabolism. There is mixed evidence to support the role of host factors such as age, sex, and chronic liver disease in the development of DILI. For specific drugs, a genetic predisposition appears to be a risk factor for DILI. Suspected cases of idiosyncratic DILI should be categorized as hepatitic, cholestatic, or mixed on the basis of the degree/ratio of abnormalities in the alanine aminotransferase and alkaline phosphatase. A careful evaluation for other causes of liver disease should be performed, though a liver biopsy is rarely needed. There is evidence that some patients with DILI may actually have hepatitis E and this diagnosis should be considered. Amoxicillin/clavulanate isoniazid, and nonsteroidal anti-inflammatory drugs are among the most common causes of DILI. Drug discontinuation or dechallenge should lead to an improvement in liver biochemistries in most patients, though a bilirubin value of more than 3 g/dL is associated with mortality of at least 10%. New biomarkers for DILI using proteomics and micro RNA appear promising but require further study. New studies on drugs with potential for causing DILI are reviewed herein, including tumor necrosis factor-alpha antagonists, fluoroquinolones, tyrosine kinase inhibitors, statins, and supplements. PubMed was used with search terms of drug induced liver injury OR DILI with filter settings of "English language" and "humans" and custom date range of "January 1, 2000." The authors also manually searched bibliographies from key references and included seminal references before the year 2000. (C) 2014 Mayo Foundation for Medical Education and Research
引用
收藏
页码:95 / 106
页数:12
相关论文
共 60 条
  • [1] Drug-induced liver injury
    Abboud, Gebran
    Kaplowitz, Neil
    [J]. DRUG SAFETY, 2007, 30 (04) : 277 - 294
  • [2] Drug-induced liver injury:: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period
    Andrade, RJ
    Lucena, MI
    Fernández, MC
    Pelaez, G
    Pachkoria, K
    García-Ruiz, E
    García-Munoz, B
    González-Grande, R
    Pizarro, A
    Durán, JA
    Jiménez, M
    Rodrigo, L
    Romero-Gomez, M
    Navarro, JM
    Planas, R
    Costa, J
    Borras, A
    Soler, A
    Salmerón, J
    Martin-Vivaldi, R
    [J]. GASTROENTEROLOGY, 2005, 129 (02) : 512 - 521
  • [3] The Myth of Statin-Induced Hepatotoxicity
    Bader, Ted
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05) : 978 - 980
  • [4] Serum proteomic profiling in patients with drug-induced liver injury
    Bell, L. N.
    Vuppalanchi, R.
    Watkins, P. B.
    Bonkovsky, H. L.
    Serrano, J.
    Fontana, R. J.
    Wang, M.
    Rochon, J.
    Chalasani, N.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (05) : 600 - 612
  • [5] Drug-Induced Autoimmune Hepatitis: Clinical Characteristics and Prognosis
    Bjoernsson, Einar
    Talwalkar, Jayant
    Treeprasertsuk, Sombat
    Kamath, Patrick S.
    Takahashi, Naoki
    Sanderson, Schuyler
    Neuhauser, Matthias
    Lindor, Keith
    [J]. HEPATOLOGY, 2010, 51 (06) : 2040 - 2048
  • [6] Outcome and prognostic markers in severe drug-induced liver disease
    Björnsson, E
    Olsson, R
    [J]. HEPATOLOGY, 2005, 42 (02) : 481 - 489
  • [7] Björnsson E, 2012, J HEPATOL, V56, P374, DOI [10.1016/j.jhep.2011.08.016, 10.1016/j.jhep.2011.07.023]
  • [8] Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland
    Bjornsson, Einar S.
    Bergmann, Ottar M.
    Bjornsson, Helgi K.
    Kvaran, Runar B.
    Olafsson, Sigurdur
    [J]. GASTROENTEROLOGY, 2013, 144 (07) : 1419 - U168
  • [9] Effect of L-carnitine treatment for valproate-induced hepatotoxicity
    Bohan, TP
    Helton, E
    McDonald, I
    König, S
    Gazitt, S
    Sugimoto, T
    Scheffner, D
    Cusmano, L
    Li, S
    Koch, G
    [J]. NEUROLOGY, 2001, 56 (10) : 1405 - 1409
  • [10] Review article: herbal and dietary supplement hepatotoxicity
    Bunchorntavakul, C.
    Reddy, K. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (01) : 3 - 17